Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and…
| Price | $0.96 |
|---|---|
| Market cap | $122.11M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 0.681-4.31 |
| Beta | 0.87 |
Explore NAUT's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.